Association of Diabetes Care & Education Specialists

Home Page
Your Personalized Guide
to AADE Resources
My Profile
My Memberships
My Purchases
My Open Invoices
Join Online
Online Store
Make a Donation
Access My Learning
Access AADE7 System
Find a Diabetes Educator
Find an Accredited DSME Program
Apply For/Manage My DEAP Application

Event Profile

Let's Talk About Afrezza® (insulin human) Inhalation Powder, the Inhaled Insulin for Mealtime Control

June 20, 2019

Location: Online


This webinar is FREE 

Event Date: Thursday, June 20, 2019
Event Time: 1:00–1:45 p.m. Eastern Time

Please Note: All times are Eastern. Our webinars begin at 1:00 pm Eastern / 12:00 noon Central / 11:00 am Mountain / 10:00 am Pacific.

Program Overview

This webinar is sponsored by MannKind Corporation.

Mealtime glucose control isn’t always easy for today’s patients. AFREZZA, the only inhaled insulin on the market with an ultra-rapid absorption feature, delivers mealtime glucose control in a unique way.

There is no CE credit for this webinar. 


-- Learn how AFREZZA can help patients with type 1 and type 2 diabetes achieve optimal mealtime glucose control in a unique way
-- Gain an understanding of how to dose & titrate AFREZZA for both type 1 and type 2 patients
-- Learn how to get patients started to help ensure a successful start with AFREZZA


Nadia Zaveri, PharmD
Medical and Clinical Affairs Advisor

Mark Harmel, MPH, CDE
Clinical Research Coordinator
USC Westside Center for Diabetes

Intended Audience

This LIVE webinar is open to AADE members and non-members.

This webinar will be recorded and posted in DANA (, AADE's member-only tech hub. The recorded webinar will be available to AADE members only.

Test Your Computer

To ensure that your participation is successful, please test your system as soon as possible so if you do have technical challenges, you will have time to get them sorted out. Click here to test your computer.

System Requirements

While you can participate with a 56K dialup internet connection, it is recommended that you have a high-speed broadband (or better) internet connection. Please be sure you close as many open programs on your system as possible.

Click here for operating system requirements

• Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA.
• AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.
• Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.

Indications and Usage 
Afrezza (insulin human) Inhalation Powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use
• AFREZZA is not a substitute for long-acting insulin. AFREZZA must be used in combination with long-acting insulin in patients with type 1 diabetes mellitus.
• AFREZZA is not recommended for the treatment of diabetic ketoacidosis.
• The safety and efficacy of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking (less than 6 months).

AFREZZA is contraindicated in patients:
• During episodes of hypoglycemia
• With chronic lung disease (such as asthma or chronic obstructive pulmonary disease [COPD]) because of the risk of acute bronchospasm
• With hypersensitivity to regular human insulin or any of the AFREZZA excipients

Warnings and Precautions

Acute Bronchospasm: Before initiating therapy, evaluate patients with a medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease. Acute bronchospasm has been observed following AFREZZA dosing in patients with asthma and patients with COPD. The long-term safety and efficacy of AFREZZA in patients with chronic lung disease have not been established.

Changes in Insulin Regimen: Monitor blood glucose in all patients treated with insulin. Modify insulin regimen and dose cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment to help mitigate the risk of hypoglycemia or hyperglycemia.

Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin therapy, including AFREZZA, and may be serious and life-threatening. Educate patients and caregivers on mitigating the risks associated with hypoglycemia. Increased frequency of blood glucose monitoring is recommended for patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia.

Decline in Pulmonary Function: AFREZZA has been shown to cause a decrease in lung function as measured by FEV1. In clinical trials lasting up to 2 years, AFREZZA treated patients experienced a small (40 mL) but greater FEV1decline than comparator-treated patients. Assess pulmonary function with spirometry at baseline, after the initial 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA.

Lung Cancer: In clinical trials, 2 cases of lung cancer were reported in patients exposed to AFREZZA while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell and lung blastoma) were reported in non-smokers exposed to AFREZZA after the trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA outweigh the risks.

Diabetic Ketoacidosis (DKA): Increase the frequency of glucose monitoring and consider an alternate route of administration of insulin in patients at risk for DKA.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including AFREZZA. If hypersensitivity reactions occur, discontinue AFREZZA, treat per standard of care and monitor if indicated.

Hypokalemia: Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of TZDs and insulin. Observe these patients for signs and symptoms of heart failure. If heart failure occurs, manage according to current standards and consider TZD dose reduction or discontinuation.

Adverse Reactions
The most common adverse reactions associated with AFREZZA (2% or greater incidence) are hypoglycemia, cough, and throat pain or irritation.

Drug Interactions
Certain drugs may affect glucose metabolism, increasing the risk of hypoglycemia or decreasing the blood glucose lowering effect of AFREZZA. Dose adjustment and increased frequency of blood glucose monitoring may be required. Co-administration of beta-blockers, clonidine, guanethidine, and reserpine with AFREZZA may reduce the signs and symptoms of hypoglycemia. Full Prescribing Information, including BOXED WARNING, is available on


Share with friends: